The Board of Directors of Syngene International Limited, in their meeting held on May 18, 2026, has provided in-principle approval for the voluntary liquidation of its wholly owned subsidiary, Syngene Manufacturing Solutions Limited (SMSL). As SMSL does not have any active business operations, this process is being conducted under the Insolvency and Bankruptcy Code, 2016, and the relevant Insolvency and Bankruptcy Board of India regulations for solvent companies.

Syngene International Limited is a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO) headquartered in Bengaluru, India. The company offers integrated scientific services across the entire value chain—from early discovery and pre-clinical development to clinical trials and commercial manufacturing—serving clients in the pharmaceutical, biotechnology, animal health, consumer goods, and agrochemical industries. In recent developments, Syngene has focused on expanding its infrastructure and capabilities, including its biologics and peptide manufacturing units, to support its growing project pipeline. Furthermore, the company extended its strategic research partnership with Bristol Myers Squibb through 2035.

The liquidation of SMSL is considered a routine administrative measure and is expected to have no material impact on the company’s consolidated financials, as the subsidiary contributed 0.00% to the turnover and only 0.02% to the net worth of the company for the financial year ended March 31, 2026. As a company with significant institutional backing, Syngene counts Biocon Limited as its promoter, alongside substantial holdings by various mutual funds and foreign institutional investors.